Organization: MaRS Innovation

Pfizer Canada funds MaRS Innovation for health sciences research

Pfizer Canada has contributed $800,000 to MaRS Innovation to support new ideas or technologies in health sciences research in areas of therapeutics, diagnostic and treatment tools, and manufacturing technologies. The MaRS Innovation – Pfizer Translational Research Fund will be managed by MaRS Innovation. Priority projects are in cardiovascular disease, inflammation, immunology, rare diseases, vaccines, and…

Encycle raises $2.85 million in start-up funding

Encycle Therapeutics Inc has completed financing of $2.85 million to support development of its nacellin platform chemistry and advance its therapeutics pipeline. The investment in the Toronto-based firm — spun off from the Univ of Toronto in collaboration with MaRS Innovation — will allow it to build on its relationships with pharmaceutical companies and position…

ChipCare finalizes $5-million series A financing

ChipCare Corp has closed a $5-million series A financing to bring its handheld, blood-testing platform for HIV and other infectious and non-communicable diseases to market. Financing for the Univ of Toronto start-up was led by Puffin Partners LP, Dallas TX, and includes MaRS Innovation, Maple Leaf Angels, Winfield Venture Group, Epic Capital and US and…

ChipCare finalizes $5-million series A financing

ChipCare Corp has closed a $5-million series A financing to bring its handheld, blood-testing platform for HIV and other infectious and non-communicable diseases to market. Financing for the Univ of Toronto start-up was led by Puffin Partners LP, Dallas TX, and includes MaRS Innovation, Maple Leaf Angels, Winfield Venture Group, Epic Capital and US and…

AvidBiologics completes VC financing round

Toronto-based AvidBiologics Inc has closed a financing round to move its antibody-drug conjugate (ADC) technologies into clinical trials. The privately held firm — a 2011 spinout from YM BioSciences Inc — secured an unspecified amount of financing from Lumira Capital (lead), MaRS Investment Accelerator Fund, MaRS Innovation, Rosseau Asset Management and the company’s founding investors.…

Three CECRs receive $4 million from Merck Canada

Merck Canada is investing $4 million in three Centres of Excellence for Commercialization and Research (CECR) as part of a $100-million commitment it made in 2010 when it closed its Merck Frosst Centre for Therapeutic Research in a global restructuring (R$, July 19/10). The funding goes to the Institute for Research in Immunology and Cancer…

CECR and BL-NCE funding extensions announced

The Networks of Centres of Excellence (NCE) secretariat has released the results of its competition to determine which of the original recipients of its two industry-facing programs will receive extended funding. The competition awarded renewed funding for four of the original 11 Centres of Excellence for Commercialization and Research (CECR) and one of the four…